Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 179

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Safety and Efficacy of Risedronate in Reducing Fracture Risk in Osteoporotic Women Aged 80 and Older: Implications for the Use of Antiresorptive Agents in the Old and Oldest Old

Boonen, Steven, McClung, Michael R., Eastell, Richard, El‐Hajj Fuleihan, Ghada, Barton, Ian P., Delmas, Pierre · 2004 · Journal of the American Geriatrics Society

Abstract

Objectives: To determine the efficacy of risedronate in reducing vertebral fracture risk in women aged 80 and older with osteoporosis. Design: Pooled analysis of data from three randomized, double‐blind, controlled, 3‐year‐fracture‐endpoint trials conducted from November 1993 to April 1998: Hip Intervention Program (HIP), Vertebral Efficacy with Risedronate Therapy—Multinational (VERT‐MN), and VERT‐North America (NA). Setting: Office‐based practices, research centers, and osteoporosis clinics in Europe, North America, and Australia. Participants: Osteoporotic (femoral neck bone mineral density T‐score < −2.5 standard deviations or at least one prevalent vertebral fracture) women aged 80 and older. Intervention: Patients received placebo (n=688) or risedronate 5 mg/d (n=704) for up to 3 years. All patients received 1,000 mg/d calcium and, if baseline levels were low, up to 500 IU/d vitamin D. Measurements: Cumulative incidence of new vertebral fractures. Results: After 1 year, the risk of new vertebral fractures in the risedronate group was 81% lower than with placebo (95% confidence interval=60–91%; P< .001). The number of women who needed to be treated to prevent one new vertebral fracture after 1 year was 12. This early onset of efficacy was consistent across the clinical programs, and antifracture efficacy was confirmed over 3 years. Risedronate was well tolerated, with a safety profile comparable with that of placebo. Conclusion: These findings provide the first evidence that, even in the very old, reducing bone resorption rate remains an effective treatment strategy for osteoporosis. Because each therapeutic agent used for the treatment of osteoporosis may have unique characteristics, the observations made in this study should not be assumed to apply to other bisphosphonates.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1532-5415.2004.52506.x

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 179

Metadata

Authors
Boonen, S., McClung, M. R., Eastell, R., El‐Hajj Fuleihan, G., Barton, I. P., & Delmas, P.
Venue
Journal of the American Geriatrics Society
Publisher
Wiley
Published
2004-10-26
Volume
52
Issue
11
Pages
1832-1839
ISSN
  • 0002-8614 (ISSN-L)
  • 1532-5415
OpenAlex
W2133639396
Cited by
179
References
6
FWCI
13.63
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and Efficacy of Risedronate in Reducing Fracture Risk in Osteoporotic Women Aged 80 and Older: Implications for the Use of Antiresorptive Agents in the Old and Oldest Old. https://app.cochat.ai/papers/10.1111/j.1532-5415.2004.52506.x
The paper
Boonen, S., McClung, M. R., Eastell, R., El‐Hajj Fuleihan, G., Barton, I. P., & Delmas, P. (2004). Safety and Efficacy of Risedronate in Reducing Fracture Risk in Osteoporotic Women Aged 80 and Older: Implications for the Use of Antiresorptive Agents in the Old and Oldest Old. Journal of the American Geriatrics Society. https://doi.org/10.1111/j.1532-5415.2004.52506.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.